Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L and 9 more

Show all authors

Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L

JAMA1 Aug 2026

PMID42251595DOI10.1001/jama.2026.8142PepBankPUB-42251595

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity, mazdutide 9 mg reduced body weight more than placebo at week 60 (between-group difference -15.15%, P < .001).
In plain wordsIn Chinese adults with obesity, mazdutide 9 mg lowered body weight more than placebo after 60 weeks.
Peptide
Mazdutide
Outcome
DecreasePercent change in body weight at week 60
Study
n = 461
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Body weight change
−16.65%
mazdutide 9 mg
Body weight change
−1.5%
placebo
Between-group difference in body weight
−15.15%
mazdutide 9 mg vs placebo
Source sentences
Summary
At week 60, the mean percentage change in body weight from baseline was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group compared with -1.50% (95% CI, -3.43% to 0.43%) in the placebo group (between-group difference, -15.15% [95% CI, -17.22% to -13.09%]; P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159501
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity, 84.3% of participants on mazdutide 9 mg lost at least 5% of body weight versus 33.1% on placebo at week 60 (P < .001).
In plain wordsIn Chinese adults with obesity, more people on mazdutide 9 mg than on placebo lost at least 5% of body weight after 60 weeks.
Peptide
Mazdutide
Outcome
IncreaseProportion with body weight reduction of at least 5% at week 60
Study
n = 461
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Proportion with weight reduction of 5% or more
84.3%
mazdutide 9 mg
Proportion with weight reduction of 5% or more
33.1%
placebo
Source sentences
Summary
At week 60, 84.3% of participants in the mazdutide group had a body weight reduction of 5% or greater compared with 33.1% in the placebo group (between-group difference, 51.6% [95% CI, 43.0% to 60.1%]; P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159502
03HumanRandomized controlled trialSafety outcome
In Chinese adults with obesity, adverse events led to treatment discontinuation in 2.9% on mazdutide 9 mg and 0% on placebo.
In plain wordsIn Chinese adults with obesity, side effects made a few more people stop mazdutide 9 mg than placebo.
Peptide
Mazdutide
Outcome
IncreaseAdverse events leading to treatment discontinuation
Study
n = 461
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Discontinuation due to adverse events
2.9%
mazdutide 9 mg
Discontinuation due to adverse events
0%
placebo
Source sentences
Summary
Adverse events leading to study treatment discontinuation were reported in 2.9% of participants in the mazdutide group compared with 0% in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159503
04HumanRandomized controlled trialSafety outcome
In Chinese adults with obesity, vomiting occurred more often with mazdutide 9 mg than with placebo (53.1% versus 1.3%).
In plain wordsIn Chinese adults with obesity, vomiting was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseVomiting
Study
n = 461
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Vomiting incidence
53.1%
mazdutide 9 mg
Vomiting incidence
1.3%
placebo
Source sentences
Summary
The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%); most of the adverse events were mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159504
05HumanRandomized controlled trialSafety outcome
In Chinese adults with obesity, nausea occurred more often with mazdutide 9 mg than with placebo (46.9% versus 3.2%).
In plain wordsIn Chinese adults with obesity, nausea was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseNausea
Study
n = 461
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Nausea incidence
46.9%
mazdutide 9 mg
Nausea incidence
3.2%
placebo
Source sentences
Summary
The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%); most of the adverse events were mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159505
06HumanRandomized controlled trialSafety outcome
In Chinese adults with obesity, diarrhea occurred more often with mazdutide 9 mg than with placebo (39.4% versus 6.5%).
In plain wordsIn Chinese adults with obesity, diarrhea was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseDiarrhea
Study
n = 461
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · subcutaneous · 60 weeksAs given in this study (human).
Measurements
Diarrhea incidence
39.4%
mazdutide 9 mg
Diarrhea incidence
6.5%
placebo
Source sentences
Summary
The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%); most of the adverse events were mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n = 308) or placebo (n = 154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.
Summary · context
A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses.
Report a problemFND-4225159506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT06164873

A Study of IBI362 9 mg in Chinese Adults With Obesity

Innovent Biologics (Suzhou) Co. Ltd.n = 46227 Dec 2023 to est. 19 Sept 2025

Obesity

Trial page ClinicalTrials.govUpdated 27 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.